Meta Platforms Inc vs TransMedics Group Inc — how do they compare? Meta Platforms Inc trades at $601.4 (market cap $1.53T), while TransMedics Group Inc trades at $89.4 (market cap $3.10B). The key difference: Meta Platforms Inc is far larger — about 493.5× TransMedics Group Inc's market cap, and Meta Platforms Inc pays a 0.35% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| META | TMDX | |
|---|---|---|
Market Cap | $1.53T | $3.10B |
Volume | 24,093,972 | — |
Sector | Media | Technology |
52-Week High | $790.00 | $150.42 |
52-Week Low | $525.72 | $61.99 |
Enterprise Value | $1.55T | $3.49B |
Dividend Yield | 0.35% | — |
Signals from Pluang's Aura AI — not financial advice
Meta Platforms trades at $594.92, up 0.48% with strong fundamentals including 81.75% gross margins and 29.84% net income margin. Recent Q1 2026 earnings beat expectations ($10.44 vs $6.70), though Q2 2026 missed ($6.18 vs $7.19). Technical indicators show bearish signals with current price near pivot point resistance at $598. The company maintains robust cash flow generation of $115.8B from operations in 2025.
Analyst consensus remains strongly bullish with 79% buy ratings and $761.95 price target, representing 28% upside. Key catalysts include AI leadership with Muse Spark launch and strong revenue growth trajectory. Risks include regulatory lawsuits, high capital expenditures, and competitive pressures in social media and AI markets.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Meta Platforms Inc., doing business as Meta and previously known as Facebook Inc. It's a company that acts as a parent platform for Facebook, Messenger, Instagram, Whatsapp, Oculus and other subsidiaries. Among these platforms, Facebook is the number one social media platform in terms of the number of active users.
Read more on META →TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →